Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 13/20 | 0.68 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6658160 | 0.89 | FBP1 (0.56) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL5483113 | 0.88 | FBP1 (0.54) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL21188516 | 0.88 | FBP1 (0.67) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL5605607 | 0.86 | ALDH1A1 (0.56) | FBP1TSHRALDH1A1POLB | |
| SCHEMBL6091768 | 0.86 | FBP1 (0.53) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL29238993 | 0.86 | ALDH1A1 (0.54) | FBP1TSHRALDH1A1POLB | |
| SCHEMBL4682766 | 0.86 | FBP1 (0.69) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL5476491 | 0.86 | FBP1 (0.53) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL28657507 | 0.86 | FBP1 (0.51) | FBP1CYP1A2TSHRALDH1A1POLB | |
| SCHEMBL1549019 | 0.85 | FBP1 (0.64) | FBP1PPARAABCB11CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3486231-B1 | PYRROLIDINE DERIVATIVE SERVING AS PPAR AGONIST | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2020-05-20 | — | — | EP | disclosed |
| US-20190225597-A1 | PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-07-25 | — | — | US | disclosed |
| EP-3486231-A1 | PYRROLIDINE DERIVATIVE SERVING AS PPAR AGONIST | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-22 | — | — | EP | disclosed |
| EP-2314576-A1 | Phenyl derivatives as PPAR agonists | F.HOFFMANN-LA ROCHE AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1513796-B1 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORP (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| EP-1682508-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| US-20060074111-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-06 | — | — | US | disclosed |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | SMITHKLINE BEECHAM CORPORATION | 2005-10-06 | — | — | US | disclosed |
| WO-2005049578-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049573-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
| EP-1513796-A2 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1513795-A2 | PROPIONIC ACID DERIVATIVES AND THEIR USE AS HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000785-A2 | PHENYLOXYALKANONIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000762-A2 | PROPIONIC ACID DERIVATIVES AND THEIR USE AS HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | PPARD, PPARA, PPARG | FBP1 1195/4885PPARA 2/4885ABCB11 1315/4885 |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | CEL, HPN, LIPA | FBP1 393/4885PPARA 54/4885ABCB11 18/4885 |
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | FBP1 1895/4885PPARA 2/4885ABCB11 337/4885 |
| US-20060074111-A1 | Chemical compounds | HDAC3, HAT1, H1-3 | FBP1 728/4885PPARA 2913/4885ABCB11 300/4885 |
| US-20190225597-A1 | PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | PPARD, PPARA, PPARG | FBP1 1668/4885PPARA 2/4885ABCB11 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.